$OCUL
OCULAR THERAPEUTIX, INC

2021 Q4 Form 10-Q Financial Statement

#000155837021015029 Filed on November 08, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $12.31M $12.15M $5.876M
YoY Change 67.46% 106.82% 608.81%
Cost Of Revenue $1.108M $1.310M $450.0K
YoY Change 62.94% 191.11% -44.17%
Gross Profit $11.20M $10.84M $5.426M
YoY Change 67.92% 99.83% 23491.3%
Gross Profit Margin 91.0% 89.22% 92.34%
Selling, General & Admin $16.67M $17.65M $12.48M
YoY Change 24.5% 41.44% -3.49%
% of Gross Profit 148.85% 162.81% 230.02%
Research & Development $12.58M $12.72M $6.951M
YoY Change 65.07% 82.98% -32.09%
% of Gross Profit 112.3% 117.3% 128.11%
Depreciation & Amortization $570.0K $594.0K $670.0K
YoY Change -13.64% -11.34% 0.0%
% of Gross Profit 5.09% 5.48% 12.35%
Operating Expenses $29.25M $30.37M $19.43M
YoY Change 39.21% 56.3% -16.12%
Operating Profit -$18.05M -$19.53M -$14.01M
YoY Change 25.86% 39.43% -39.48%
Interest Expense $14.20M $1.658M $1.715M
YoY Change -119.92% -3.32% 3.88%
% of Operating Profit
Other Income/Expense, Net $1.000K $22.19M $2.062M
YoY Change 975.95% -52.77%
Pretax Income -$3.850M $2.657M -$11.94M
YoY Change -95.5% -122.25% -36.42%
Income Tax
% Of Pretax Income
Net Earnings -$3.850M $2.657M -$11.94M
YoY Change -95.5% -122.25% -36.39%
Net Earnings / Revenue -31.28% 21.86% -203.27%
Basic Earnings Per Share $0.03 -$0.19
Diluted Earnings Per Share -$50.25K -$0.23 -$0.21
COMMON SHARES
Basic Shares Outstanding 76.61M 76.55M 62.99M
Diluted Shares Outstanding 85.45M 68.76M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $164.2M $179.3M $70.60M
YoY Change -28.03% 153.94% 7.95%
Cash & Equivalents $164.2M $179.3M $70.64M
Short-Term Investments
Other Short-Term Assets $4.751M $3.877M $2.300M
YoY Change 1.09% 68.57% 4.55%
Inventory $1.250M $1.222M $1.154M
Prepaid Expenses
Receivables $21.14M $19.55M $7.779M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $191.3M $203.9M $81.90M
YoY Change -22.29% 148.99% 17.68%
LONG-TERM ASSETS
Property, Plant & Equipment $6.956M $6.914M $8.490M
YoY Change -14.07% -18.56% -50.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.764M $1.764M $1.800M
YoY Change -2.0% -2.0% 0.0%
Total Long-Term Assets $13.59M $13.81M $16.32M
YoY Change -13.48% -15.38% -14.58%
TOTAL ASSETS
Total Short-Term Assets $191.3M $203.9M $81.90M
Total Long-Term Assets $13.59M $13.81M $16.32M
Total Assets $204.9M $217.7M $98.22M
YoY Change -21.76% 121.69% 10.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.592M $4.246M $3.238M
YoY Change 69.51% 31.13% -7.49%
Accrued Expenses $20.12M $19.36M $12.17M
YoY Change 40.64% 59.13% 62.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $6.200M
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $26.34M $25.16M $22.91M
YoY Change -1.23% 9.83% 108.24%
LONG-TERM LIABILITIES
Long-Term Debt $51.44M $50.82M $42.80M
YoY Change 24.84% 18.74% -11.02%
Other Long-Term Liabilities $39.12M $54.42M $36.70M
YoY Change -66.82% 48.28% 100.55%
Total Long-Term Liabilities $90.55M $105.2M $79.50M
YoY Change -43.09% 32.38% 19.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.34M $25.16M $22.91M
Total Long-Term Liabilities $90.55M $105.2M $79.50M
Total Liabilities $116.9M $130.4M $102.3M
YoY Change -37.08% 27.41% 32.23%
SHAREHOLDERS EQUITY
Retained Earnings -$545.8M -$542.0M -$453.6M
YoY Change 1.22% 19.47%
Common Stock $633.8M $629.3M $449.5M
YoY Change 3.0% 39.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $88.00M $87.34M -$4.126M
YoY Change
Total Liabilities & Shareholders Equity $204.9M $217.7M $98.22M
YoY Change -21.76% 121.69% 10.73%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$3.850M $2.657M -$11.94M
YoY Change -95.5% -122.25% -36.39%
Depreciation, Depletion And Amortization $570.0K $594.0K $670.0K
YoY Change -13.64% -11.34% 0.0%
Cash From Operating Activities -$15.15M -$12.98M -$13.66M
YoY Change 142.84% -4.96% -30.09%
INVESTING ACTIVITIES
Capital Expenditures -$631.0K -$276.0K -$220.0K
YoY Change 152.4% 25.45% -47.62%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$631.0K -$276.0K -$220.0K
YoY Change 152.4% 25.45% -47.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 667.0K 679.0K 220.0K
YoY Change -99.59% 208.64% -98.82%
NET CHANGE
Cash From Operating Activities -15.15M -12.98M -13.66M
Cash From Investing Activities -631.0K -276.0K -220.0K
Cash From Financing Activities 667.0K 679.0K 220.0K
Net Change In Cash -15.12M -12.58M -13.66M
YoY Change -109.6% -7.91% 911.85%
FREE CASH FLOW
Cash From Operating Activities -$15.15M -$12.98M -$13.66M
Capital Expenditures -$631.0K -$276.0K -$220.0K
Free Cash Flow -$14.52M -$12.71M -$13.44M
YoY Change 142.44% -5.46% -29.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2020Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2021Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2020Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75996732
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76606968
dei Entity Central Index Key
EntityCentralIndexKey
0001393434
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36554
dei Entity Registrant Name
EntityRegistrantName
Ocular Therapeutix, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5560161
dei Entity Address Address Line1
EntityAddressAddressLine1
24 Crosby Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Bedford
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01730
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
357-4000
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
OCUL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
76610153
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
179281000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228057000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19552000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12252000
CY2021Q3 us-gaap Inventory Net
InventoryNet
1222000
CY2020Q4 us-gaap Inventory Net
InventoryNet
1201000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3877000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4650000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
203932000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
246160000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6914000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8095000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5129000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5844000
CY2021Q3 us-gaap Assets
Assets
217739000
CY2020Q4 us-gaap Assets
Assets
261863000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4246000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2709000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19358000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14307000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1554000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1358000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
8290000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
25158000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26664000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6355000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7548000
CY2021Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
36064000
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
98313000
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12000000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12000000
CY2021Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
24936000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
16936000
CY2021Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
25886000
CY2020Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
24307000
CY2021Q3 us-gaap Liabilities
Liabilities
130399000
CY2020Q4 us-gaap Liabilities
Liabilities
185768000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76606968
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75996732
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
8000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
629286000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
615338000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-541954000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-539251000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
87340000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
76095000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
217739000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
261863000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12153000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5876000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31214000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10054000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12153000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5876000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31214000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10054000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1310000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
450000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3298000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1403000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12719000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6951000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37505000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21070000
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9576000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6520000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
26054000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
19803000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8077000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5961000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24345000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16282000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
31682000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
19882000
us-gaap Costs And Expenses
CostsAndExpenses
91202000
us-gaap Costs And Expenses
CostsAndExpenses
58558000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19529000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14006000
us-gaap Operating Income Loss
OperatingIncomeLoss
-59988000
us-gaap Operating Income Loss
OperatingIncomeLoss
-48504000
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
7000
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
6000
us-gaap Investment Income Net
InvestmentIncomeNet
27000
us-gaap Investment Income Net
InvestmentIncomeNet
162000
CY2021Q3 us-gaap Interest Expense
InterestExpense
1658000
CY2020Q3 us-gaap Interest Expense
InterestExpense
1715000
us-gaap Interest Expense
InterestExpense
4991000
us-gaap Interest Expense
InterestExpense
5042000
CY2021Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
23837000
CY2020Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
3771000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
62249000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-16640000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22186000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2062000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
57285000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21520000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
2657000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-11944000
us-gaap Net Income Loss
NetIncomeLoss
-2703000
us-gaap Net Income Loss
NetIncomeLoss
-70024000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76552060
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62992558
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76317563
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57440885
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85446886
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68761790
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82086795
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57440885
us-gaap Profit Loss
ProfitLoss
-2703000
us-gaap Profit Loss
ProfitLoss
-70024000
us-gaap Share Based Compensation
ShareBasedCompensation
11136000
us-gaap Share Based Compensation
ShareBasedCompensation
5427000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3440000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3279000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
62249000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-16640000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1851000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2106000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7300000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5231000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-773000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
97000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
21000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
200000
ocul Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-715000
ocul Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-593000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1430000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
113000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3529000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
911000
ocul Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-997000
ocul Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-825000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50397000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47308000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
563000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
588000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-563000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-588000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
3722000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2414000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1044000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
490000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
350000
ocul Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
3201000
ocul Repayment Of Paycheck Protection Program Loan
RepaymentOfPaycheckProtectionProgramLoan
3201000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
-275000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62707000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4167000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2184000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64101000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-48776000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16205000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229821000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56201000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
181045000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72406000
us-gaap Interest Paid Net
InterestPaidNet
1443000
us-gaap Interest Paid Net
InterestPaidNet
1769000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
199000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
71000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
76095000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1197000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
91000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3086000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
3121000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
83408000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
538000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
490000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4292000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8481000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
80247000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
678000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3758000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
2657000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
87340000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-3630000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
128000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12690000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1665000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-21512000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-10659000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
378000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
350000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50017000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1826000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-36568000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
5344000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
538000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1936000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-11944000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-4126000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-541954000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
179281000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.13;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, clinical trial accruals and the fair value of derivatives.  Actual results may differ from these estimates.  The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, and those of its customers, vendors, suppliers, and collaboration partners, will depend on future developments that are highly uncertain, subject to change and difficult to predict, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international customers and markets. </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk and of Significant Suppliers and Customers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24.45pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">The Company is dependent on a small number of third-party manufacturers to supply products for research and development activities in its preclinical and clinical programs and for sales of its products. The Company’s development </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">programs as well as revenue from future sales of its product sales could be adversely affected by a significant interruption in the supply of any of the components of these products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">For the three and nine months ended September 30, 2021, three specialty distributor customers accounted for 44%, 28%, and 16%, and 44%, 26% and 15%<span style="white-space:pre-wrap;">, respectively, of the Company’s total revenue, and no other customer accounted for more than 10% of the Company’s total revenue. At September 30, 2021, </span>three specialty distributor customers accounted for 49%, 27% and 16% of the Company’s total accounts receivable and no other customer accounted for more than 10% of the Company’s total accounts receivable at September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;">For the three and nine months ended September 30, 2020, three specialty distributor customers accounted for 39%, 38% and 10% and 40%, 30% and 12%<span style="white-space:pre-wrap;">, respectively, of the Company’s total revenue and no other customer accounted for more than 10% of total revenue. At December 31, 2020, </span>three specialty distributor customers accounted for 45%, 33% and 15% of the Company’s total accounts receivable and no other customer accounted for more than 10% of the Company’s total accounts receivable at December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72406000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
179281000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70642000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1764000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
181045000
CY2021Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
370000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
384000
CY2021Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
563000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
232000
CY2021Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
289000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
585000
CY2021Q3 us-gaap Inventory Net
InventoryNet
1222000
CY2020Q4 us-gaap Inventory Net
InventoryNet
1201000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6757000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5853000
CY2021Q3 ocul Accrued Rebates And Programs Current
AccruedRebatesAndProgramsCurrent
3100000
CY2020Q4 ocul Accrued Rebates And Programs Current
AccruedRebatesAndProgramsCurrent
1438000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1387000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
868000
CY2021Q3 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1180000
CY2020Q4 ocul Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1013000
CY2021Q3 ocul Debt Instrument Accrued Interest
DebtInstrumentAccruedInterest
5900000
CY2020Q4 ocul Debt Instrument Accrued Interest
DebtInstrumentAccruedInterest
4194000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1034000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
941000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19358000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14307000
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
98313000
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
62249000
CY2021Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
36064000
CY2021Q3 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2021Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
25000000
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
25000000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
25000000
CY2021Q3 ocul Debt Instrument Exit Fees Payable
DebtInstrumentExitFeesPayable
54000
CY2020Q4 ocul Debt Instrument Exit Fees Payable
DebtInstrumentExitFeesPayable
355000
CY2021Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
118000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
129000
CY2021Q3 us-gaap Notes Payable
NotesPayable
24936000
CY2020Q4 us-gaap Notes Payable
NotesPayable
25226000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
8290000
CY2021Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
24936000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
16936000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
2657000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-11944000
us-gaap Net Income Loss
NetIncomeLoss
-2703000
us-gaap Net Income Loss
NetIncomeLoss
-70024000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76552060
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62992558
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76317563
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57440885
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2657000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11944000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2703000
CY2021Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
1113000
CY2020Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
1069000
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
3286000
CY2021Q3 us-gaap Dilutive Securities
DilutiveSecurities
-23837000
CY2020Q3 us-gaap Dilutive Securities
DilutiveSecurities
-3771000
us-gaap Dilutive Securities
DilutiveSecurities
-62249000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20067000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14646000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-61666000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76552060
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62992558
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76317563
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3125594
CY2021Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
CY2020Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
5769232
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85446886
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68761790
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82086795
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3226777
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8989728
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5427000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
23248000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10948312
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8989728
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11136000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3758000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1936000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000

Files In Submission

Name View Source Status
0001558370-21-015029-index-headers.html Edgar Link pending
0001558370-21-015029-index.html Edgar Link pending
0001558370-21-015029.txt Edgar Link pending
0001558370-21-015029-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ocul-20210930.xsd Edgar Link pending
ocul-20210930x10q.htm Edgar Link pending
ocul-20210930x10q_htm.xml Edgar Link completed
ocul-20210930xex31d1.htm Edgar Link pending
ocul-20210930xex31d2.htm Edgar Link pending
ocul-20210930xex32d1.htm Edgar Link pending
ocul-20210930xex32d2.htm Edgar Link pending
ocul-20210930_cal.xml Edgar Link unprocessable
ocul-20210930_def.xml Edgar Link unprocessable
ocul-20210930_lab.xml Edgar Link unprocessable
ocul-20210930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending